Legal Landscape of Peptides in Sports

Two rule sets, two different questions

Fat-loss and recovery peptides fall under two sets of rules that were never designed to line up. Drug regulators such as the FDA decide whether a product can be legally sold for human use. The World Anti-Doping Agency (WADA), through its Prohibited List, decides whether an athlete in an anti-doping program may use or possess it. They often give different answers about the same compound.

Semaglutide shows the gap. As a prescription medicine (Wegovy, Ozempic), it's legal to use with a prescription, and as of October 2026 it isn't on WADA's Prohibited List. The same molecule sold online as a "research" vial is, in FDA's view, an unapproved new drug. BPC-157 runs the other way: its US compounding status has shifted several times since 2023, while WADA has kept it prohibited at all times.

How FDA treats "research use only" peptides

Most peptides lifters buy for fat loss or recovery come from websites that label them "for research use only" or "not for human consumption." FDA's 2026 enforcement shows how little protection that label gives a seller.

In warning letters dated March 31 and August 24, 2026, FDA told several online sellers that those statements didn't change what the products were. The agency pointed to evidence on the sellers' own websites that the vials were meant for people. Retatrutide and semaglutide were among the products it classed as unapproved new drugs. FDA also treated bacteriostatic water sold alongside the peptides as a drug, because selling the two together showed they were meant to be mixed and injected.

Those letters went to companies. The violation FDA cites is introducing unapproved drugs into interstate commerce, which is something a seller does. Anabolic steroids work differently, since they're federally controlled substances; none of the peptides on this page appears on the DEA's current controlled substances list. That doesn't make personal use sanctioned or safe. It means the 2026 enforcement we found targeted sellers rather than buyers.

Compounding: what changed from 2023 to 2026

For a time, some clinics prescribed BPC-157 through compounding pharmacies. FDA moved it into Category 2 of its interim 503A list in 2023, along with other peptides. Category 2 is for bulk substances that may pose significant safety risks, and the listing became the basis for enforcement against compounders.

Around April 22, 2026, FDA took 12 peptides out of Category 2 after their nominations were withdrawn. BPC-157 and TB-500 were among them. Removal didn't put them on the 503A bulks list, the list of substances pharmacies may compound with. The law firm Orrick described the result as "a regulatory gray area" until FDA takes final action.

On July 23-24, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding BPC-157 and TB-500 to that list. FDA's own staff had recommended against every peptide on the agenda, and the committee only advises. As of October 2026, FDA hasn't proposed a rule. The bulks list in federal regulations still names six substances, none of them peptides, and a second committee meeting on other peptides is planned before the end of February 2027.

Sermorelin is the exception lifters sometimes hear about. It was the active ingredient in Geref, an approved drug discontinued for commercial reasons rather than safety, so US pharmacies can still compound it with a prescription.

The approved fat-loss drugs sit outside all of this. Wegovy and Zepbound are prescription medicines with their own labels and manufacturing controls, and research vials of the same molecules aren't equivalent to them. For how the approved drugs compare with research-market peptides on evidence, see our overview of fat-loss peptides.

How WADA classifies fat-loss and recovery peptides

WADA's 2026 Prohibited List has been in force since January 1, 2026. The 2027 List was published in September 2026 and takes effect January 1, 2027; USADA's summary of it reports no change to where the compounds below sit.

Sermorelin is also named in S2.2.4. Everything prohibited in the table is banned at all times (in and out of competition). Ipamorelin is a typical case: WADA names it outright, even though its fat-loss evidence in humans is thin. The same goes for HGH Fragment 176-191, which WADA lists as a growth hormone fragment.

S0 is a catch-all, but a narrow one. It covers any pharmacological substance that no later section of the List addresses and that has "no current approval by any governmental regulatory health authority for human therapeutic use." TB-500 isn't an S0 substance for that reason: WADA names thymosin beta-4 "and its derivatives e.g. TB-500" under growth factors in S2.3.

Retatrutide isn't named anywhere on the List. As an unapproved drug still in development, it fits the S0 wording; that's our reading of the definition, and we didn't find a WADA statement naming it. USADA's advisory on the 2027 List says "peptides" in general are now named as an S0 example, and that a peptide missing from the List may still be prohibited.

Semaglutide and tirzepatide aren't prohibited. They sit in WADA's Monitoring Program, which means accredited labs test for them so WADA can track use in sport. Because they aren't prohibited, an athlete using them by prescription doesn't need a Therapeutic Use Exemption (TUE) for them as of October 2026.

Where the two rule sets interact

Approval status decides what S0 catches

The S0 test borrows its answer from drug regulators. Approval by any government health authority, in any country, takes a compound out of S0, which is why the approved GLP-1 drugs aren't caught by it. If a regulator approves retatrutide, WADA would have to decide whether another section of the List covers it. As of October 2026, it isn't approved anywhere.

Compounding isn't approval

A 503A listing would let US pharmacies compound BPC-157 for individual patients. It wouldn't make BPC-157 an approved drug, so it wouldn't move it out of S0. A prescription doesn't change sport status either. USADA's guidance is that athletes prescribed a prohibited medication should check its status and, where required, apply for a TUE before using it.

Specified versus non-specified substances

The sanction class in the table matters at a hearing. All S0 substances are "Specified," while substances in S2 and S4.4 are not. Under Article 10.2 of the 2021 World Anti-Doping Code, a first violation involving a non-specified substance carries four years of ineligibility unless the athlete proves it wasn't intentional. Then it drops to two. For a specified substance the default is two years, rising to four only if the anti-doping organization proves intent.

So a positive test for TB-500 or ipamorelin starts from a four-year default, while BPC-157 starts from two. The List itself warns that specified substances "should not in any way be considered less important or less dangerous" than others.

Possession and strict liability

Two Code rules have no counterpart in FDA's approach. Article 2.6 makes it a violation for an athlete to possess a substance that's prohibited out of competition. The exceptions are a TUE or another acceptable justification. A tested athlete can be sanctioned over a vial of TB-500 at home without ever failing a test.

Article 2.1.1 adds strict liability. Athletes are responsible for any prohibited substance found in their sample even if they didn't know it was there, and in the gray market the label isn't a reliable guide to the contents. One seller in FDA's March 2026 letters sold retatrutide as "GLP-1-R peptide" and tirzepatide as "GLP-2 peptide." An athlete who buys a "GLP-1" vial expecting a permitted drug and gets an unapproved one carries the result. We didn't find a published anti-doping case built on that scenario as of October 2026; the risk follows from how the rules are written.

If you aren't tested

WADA's rules bind athletes who compete under a Code signatory's program, such as a national anti-doping agency or an international federation. A lifter outside any testing program isn't subject to them, though FDA's rules on the product still apply. Professional leagues and the NCAA run their own drug policies, which we didn't check this cycle.

What to watch next

• Whether FDA proposes a rule after the July 2026 committee vote, and what the second advisory meeting decides before the end of February 2027.
• The 2027 Prohibited List, which takes effect on January 1, 2027. It adds "peptides" to the S0 examples.
• Whether retatrutide is approved anywhere, which would take it out of S0 as written.
• Whether WADA moves GLP-1 drugs from the Monitoring Program onto the List. As of October 2026 they're monitored only.